6 banks just lost more than $200 million on the Pfizer-Allergan collapse

The Pfizer-Allergan merger — a deal that would have been worth $160 billion — has officially been scrapped and it’s bad news for investment banks.

The two companies’ advisers could lose a combined $236 million in fees, according to Freeman & Co.

If the deal collapses, the banks may get 10% of that.

Goldman Sachs, Centerview Partners, Guggenheim, and Moelis had been advising Pfizer on the deal, while JPMorgan and Morgan Stanley were working for Allergan.

NOW WATCH: This hidden subplot of ‘Game of Thrones’ spells out the real trouble for the Lannisters

NOW WATCH: Money & Markets videos

Want to read a more in-depth view on the trends influencing Australian business and the global economy? BI / Research is designed to help executives and industry leaders understand the major challenges and opportunities for industry, technology, strategy and the economy in the future. Sign up for free at research.businessinsider.com.au.